BOSTON, Mass., July 20, 2017 – Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced it will present data from two clinical trials investigating CNTX-4975 for the treatment of pain associated with Morton’s neuroma, for which it has received both Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration (FDA). The data will be presented at the American Podiatric Medical Association’s (APMA) 2017 Annual Scientific Meeting taking place July 27-30, 2017 in Nashville, TN.

Details of the two poster presentations are listed below.

Title: CNTX-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): An Open-Label, Ascending-Dose Study
Presentation Time: 1:00-2:00 p.m. CDT, July 29, 2017
Location: Gaylord Opryland Resort and Convention Center

Title: CNTX-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects With Painful Intermetatarsal Neuroma (Morton’s Neuroma): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Presentation Time: 1:00-2:00 p.m. CDT, July 29, 2017
Location: Gaylord Opryland Resort and Convention Center

About CNTX-4975
CNTX-4975 is based on Centrexion’s proprietary STRATI™ technology (Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent, ultrapure, synthetic form of trans-capsaicin (a medicine traditionally derived from the chili plant). CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe pain without affecting touch sensibility or position sense.

CNTX-4975 works by selectively targeting the capsaicin receptor (TRPV1) to rapidly inactivate only the local pain fibers transmitting signals to the brain. With a short half-life, STRATI™ is cleared from the body within 24 hours. This approach provides pain relief that can last for months until the ends of the local pain fibers regenerate, while maintaining normal sensation, such as touch, pressure and position, and without the risks of toxicities of NSAIDs and injected corticosteroids or the side effects, including abuse and addiction, associated with opioid treatments.

About Morton’s Neuroma
Morton’s neuroma involves a thickening of the tissue around one of the nerves leading to the toes. This can cause an intense, sharp, burning pain in the foot and stinging, burning or numbness in the toes, especially when walking. Repetitive strain on the front of the foot, such as wearing high-heeled shoes or long-distance running, has been linked to the development of Morton’s neuroma. Although some people can experience relief by
switching to lower-heeled shoes with wider toe boxes or by using orthotics, many require medical intervention for the pain. The current standard of care is a corticosteroid injection. If a corticosteroid injection fails, one of the only options is surgery to remove the nerve containing the neuroma, resulting in numb toes at the site of removal. There are currently no FDA-approved treatments for Morton's neuroma.

About Centrexion Therapeutics
Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.

For more information about Centrexion, visit http://www.centrexion.com.

###

**Media Contact**
Kelly Boothe, Pure Communications, Inc.  
+1 206.349.3010  
kboothe@purecommunications.com

**Investor Contact**
Luke Heagle, Pure Communications, Inc.  
+1 910.726.1372  
lheagle@purecommunications.com